| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash (used in) provided by investing activities | -4,955 | 86,672 |
| Proceeds from sale of common stock and prefunded warrants in pipe financing | 100,002 | 100,002 |
| Proceeds from issuance of common stock under employee stock purchase plan | 24 | 24 |
| Issuance of common stock upon exercise of stock options | 26 | 26 |
| Payment of pipe financing related transaction costs | 5,625 | 5,625 |
| Deferred offering costs paid for financing | 76 | 76 |
| Net cash provided by financing activities | 94,351 | 94,351 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 9,197 | 116,202 |
| Cash and cash equivalents at beginning of period | 28,734 | - |
| Cash and cash equivalents at end of period | 37,931 | - |
Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc. (WHWK)